Recently, the group found that in chronic limb-threatening ischemia, blood flow to the muscles tends not to be reduced despite arterial blockages. On the contrary, blood flow can even increase due ...

Persistent over-dilation of muscle microvasculature may be one cause of chronic limb-threatening ischemia, recent studies by Kuopio University Hospital and the University of Eastern Finland show. In ...

The team from Doylestown Health's Vascular Surgery is the first in the greater Philadelphia region to use the Abbott ...

Cagent Vascular, Inc. announced the launch of its Serranator SL-Pro percutaneous transluminal angioplasty (PTA) serration ballo ...

UK King’s Daughters became the first hospital in Kentucky — and the only hospital in the region — to offer a new minimally invasive procedure for ...

Aplagon announces EUR 7 million financing to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2A trials: Helsinki Tuesday, February 4, 2025, 16:00 Hrs [IS ...

Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to ...

Persistent over-dilation of muscle microvasculature may be one cause of chronic limb-threatening ischemia, recent studies by Kuopio University Hospital and the University of Eastern Finland show.

Aplagon, a clinical stage biopharmaceutical company developing a first-in-class therapeutic for thrombo-inflammatory diseases, known as APAC, a heparin proteoglycan mimetic with antiplatelet and ...